NOT-NR-23-007: Notice of Clarification for the Funding Opportunity Description in PAR-22-231 "NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)"

Notice of Clarification for the Funding Opportunity Description in PAR-22-231 "NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)"

Notice Number:

NOT-NR-23-007

Key Dates

Release Date:

December 6, 2022

Related Announcements

PAR-22-231 - NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)

Issued by

National Institute of Nursing Research (NINR)

Purpose

The purpose of this Notice is to amend the Funding Opportunity Description for PAR-22-231 "NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)" as shown below:

Part. 2. Section I, Funding Opportunity Description

Non-Responsive Applications

Current Language:

Applications with the following attributes will be deemed non-responsive and will not be reviewed:

Studies of cellular function, physiological mechanisms, or gene/protein structures or relationships
Drug development research, including natural substances and dietary supplements research
Toxicology studies
Pharmacological interventions
Studies involving animal models
Studies on symptoms, symptom management, self-management, or individual health behaviors without consideration of context, i.e., meaningful incorporation of NINR research lenses in the conceptual underpinnings of the study

Modified to Read (changes shown in bold italics):

Applications with the following attributes will be deemed non-responsive and will not be reviewed:

Biological studies (e.g., cellular function, physiological mechanisms, or gene/protein structures or relationships) that do not fully integrate one or more NINR research lenses into the conceptual underpinnings and aims of the study.
Drug development research, including natural substances and dietary supplements research
Toxicology studies
Pharmacological interventions
Studies involving animal models
Studies on symptoms, symptom management, self-management, or individual health behaviors that do not fully integrate one or more NINR research lenses into the conceptual underpinnings and aims of the study.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

David L. Tilley, MPH, MS, CPH
National Institute of Nursing Research (NINR)
Email: david.tilley@nih.gov